Shareholding disclosure

Laurence Lytton

Declared position

3.02%

Threshold

Crossed upwards

Timeline

Published

22.01.2021

Transaction

11.01.2021

Voting rights breakdown

Voting rights acquired3.02%

Voting rights sold0%

Below threshold0%

Notice details

CategorySingle shareholder

ExchangeXSWX

Notification ID

TAL1K00055

Beneficial owner

Laurence Lytton

Declared address

Laurence Lytton, New-York, NY 10025

Acquisition of 200'000 American Depository Shares (ADS) listed on Nasdaq Stock Market under symbol ADXN

Open shareholder profile Open company profile

Back to the feed

Shareholding disclosure

Laurence Lytton

Addex Therapeutics Ltd22.01.2021TAL1K00055

Disclosure summary

Laurence Lytton disclosed a holding in Addex Therapeutics Ltd on the acquisition side, published by SIX Exchange Regulation on 22.01.2021, at 3.02% of voting rights. Notice category: Single shareholder.

Disclosed position

3.02%

Voting rights acquired

Voting rights acquired3.02%

Voting rights sold0%

Below threshold0%

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open

Disclosure detail

Laurence Lytton disclosed a holding in Addex Therapeutics Ltd, published on 22.01.2021.

Publication date22.01.2021

Transaction date11.01.2021

Issuing companyAddex Therapeutics Ltd

Beneficial ownerLaurence Lytton

Declared addressLaurence Lytton, New-York, NY 10025

CategorySingle shareholder

Voting rights acquired3.02%

Voting rights sold0%

Below threshold0%

ExchangeXSWX

Notification IDTAL1K00055

Conditions

Acquisition of 200'000 American Depository Shares (ADS) listed on Nasdaq Stock Market under symbol ADXN

Source: SIX Exchange Regulation · Publication date: 22.01.2021

These figures aggregate public disclosures. They are not investment advice.

insider24.ch

Never miss a market signal again

Create a free account

Need more? Discover the Pro plan

Pro alertsEmail and Telegram after publication

Unlimited company trackingUnlimited watchlist with the Pro plan

Monday recapYour stocks' essentials at the open